The United Kingdom and the United States have agreed to a significant trade agreement that will keep no import taxes on UK pharmaceutical shipments entering the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to raise funding on pharmaceuticals through the public health system. This pledge guarantees that duties on these key goods will be held at nothing for a period of the next three years.
This development is in response to recent warnings to hike tariffs on branded pharmaceutical products, with figures mentioned reaching 100%.
"This deal between the United Kingdom reinforces the global environment for innovative medicines and establishes long-overdue equity to American-British medicine commerce," an announcement said.
Economic Impact
Medicines represent one of the the United Kingdom's biggest goods shipped to the United States, which is by far the biggest market for large UK drugmakers.
Trade data reveal that in the one-year period to the end of the third quarter, the UK sold medicines worth £11.1bn to the US. This figure represented 17.4% of British export trade in that period.
"This guarantee safeguards employment, increases investment and facilitates the UK to emerge as a global hub for life sciences," a minister stated.
Key NHS Changes
The agreement includes several specific changes from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to increase overall health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, refunds were more than 20%.
Industry Background
This agreement comes amid a ongoing row between the sector and the UK government over drug pricing and regulatory access.
These tensions were intensified by claims that American customers were charged several times more for the identical medicines than consumers in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been pledged toward American operations.
One official acknowledged that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the last ten years.
